Scinai Immunotherapeutics (SCNI) Liabilities and Shareholders Equity (2015 - 2026)

Scinai Immunotherapeutics (SCNI) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $17.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $17.6 million; the trailing twelve-month figure through Mar 2026 stood at $41.1 million (up 1.22% YoY), and the FY2025 full-year result was $11.6 million, down 13.55% from the prior year.
• Liabilities and Shareholders Equity climbed to $17.6 million in Q1 2026, from $11.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $27.1 million in Q4 2022 to a low of $11.6 million in Q4 2025.
• A 5-year average of $17.9 million and a median of $17.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 11.88% in 2023, while the deepest fall reached 35.45% in 2023.
• Tracing SCNI's Liabilities and Shareholders Equity over 5 years: stood at $27.1 million in 2022, then sank by 35.45% to $17.5 million in 2023, then slipped by 23.03% to $13.4 million in 2024, then retreated by 13.55% to $11.6 million in 2025, then jumped by 51.28% to $17.6 million in 2026.
• Business Quant data shows SCNI's Liabilities and Shareholders Equity at $17.6 million in Q1 2026, $11.6 million in Q4 2025, and $11.8 million in Q2 2025.